Gain Therapeutics (GANX)

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

O preço atual after-hours da ação Gain Therapeutics, Inc. Common Stock (GANX) é de , refletindo uma variação de NaN% after-hours desde o que o mercado fechou. A capitalização de mercado da empresa é de 98,85 M $, com um volume de negociações diário de ações. O preço de fechamento anterior foi .

Pronto para começar? Siga os passos abaixo ou leia nosso guia sobre como comprar Gain Therapeutics ações na Kraken a partir de 10 $.